Tumour-induced immune modulation of sentinel lymph nodes

Nature Reviews Immunology

Volumn 6, Issue 9, 2006, Pages 659-670

  Cochran, Alistair J ^a   Huang, Rong Rong ^a   Lee, Jonathan ^b   Itakura, Eijun ^a   Leong, Stanley P L ^c   Essner, Richard ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; FLT3 LIGAND; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR VACCINE;

ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER REGRESSION; CELL MIGRATION; CHEMOTAXIS; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MEGADOSE; GENE THERAPY; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHATIC DRAINAGE; LYMPHOCYTE SUBPOPULATION; LYMPHOSCINTIGRAPHY; MELANOMA; MELANOMA CELL; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CELL MOVEMENT; DENDRITIC CELLS; HUMANS; LYMPHATIC METASTASIS; NEOPLASMS; SENTINEL LYMPH NODE BIOPSY;

EID: 33748076467     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1919     Document Type: Review

References (118)

1. Fischer, B. & Fischer, E. R. Studies concerning the regional lymph node. II. Maintenance of immunity. Cancer 27, 1001-1004 (1971).
2. Cochran, A. J. et al. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease. Anticancer Res. 9, 859-864 (1989). A summary of early studies of the immunology of tumour-draining lymph nodes oriented according to their proximity to the tumour.
3. Morton, D. L. et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 127, 392-399 (1992). The first description of the techniques of lymphatic mapping, SLN biopsy and selective lymphadenectomy.
4. Cochran, A. J. et al. The Augsburg Consensus: a commentary on the techniques of lymphatic mapping, sentinel lymphadenectomy and completion lymphadenectomy in cutaneous malignancies. Cancer 89, 236-241 (2000).
5. Cochran, A. J. et al. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod. Pathol. 14, 604-608 (2001). The first description of studies examining the immunological properties of melanoma-draining SLNs.
6. Lana, A. M., Wen, D. R. & Cochran, A. J. The morphology, immunophenotype and distribution of paracortical dendritic leukocytes in lymph nodes regional to cutaneous melanoma. Melanoma Res. 11, 401-410 (2001).
7. Matsuura, K. et al. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 106, 1227-1236 (2006).
8. Vuylsteke, R. J. et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res. 64, 8456-8460 (2004). A description of increased numbers and activation state of DCs in SLNs after the administration of GM-CSF.
9. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Rev. Immunol. 4, 941-952 (2004).
10. Lee, J. H. et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin. Cancer Res. 11, 107-112 (2005).
11. Kupper, T. S. & Fuhlbrigge, R. C. Immune surveillance in the skin: mechanisms and clinical consequences. Nature Rev. Immunol. 4, 211-222 (2004).
12. Randolph, G. J., Angeli, V. & Swartz, M. A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nature Rev. Immunol. 5, 617-628 (2005).
13. Tsakraklides, E. et al. In vitro studies of axillary lymph node cells in patients with breast cancer. J. Natl Cancer Inst. 54, 549-556 (1975).
14. Reiss, C. K., Volenec, F. J., Humphrey, M., Singla, O. & Humphrey, L. J. The role of the regional lymph node in breast cancer: a comparison between nodal and systemic reactivity. J. Surg. Oncol. 22, 249-253 (1983).
15. Kokoschka, E. M., Uchida, A., Yanagawa, E., Mickshe, M. & Kokoshka, R. Spontaneous and inducible natural cyto-toxicity in lymph-nodes draining primary melanoma. J. Invest. Dermatol. 80, 368 (1983).
16. Cochran, A. J., Pihl, E., Wen, D. R., Hoon, D. S. & Korn, E. L. Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. J. Natl Cancer Inst. 78, 399-405 (1987).
17. Wen, D.-R., Hoon, D. S. & Cochran, A. J. Variations in lymphokine generation by individual lymph nodes draining human malignant tumors. Cancer Immunol. Immunother. 30, 277-282 (1989).
18. Farzad, Z. et al. Lymphocyte subset alterations in nodes regional to human cutaneous melanoma. Cancer Res. 50, 3585-3588 (1990).
19. Morton, B. A., Ramey, W. G., Paderon, H. & Moller, R. E. Monoclonal antibody-defined phenotypes of regional lymph nodes and peripheral blood lymphocyte subpopulations in early breast cancer. Cancer Res. 46, 2121-2126 (1986).
20. Farzad, Z. et al. Lymphocytes from lymph nodes at different distances from human melanoma vary in their capacity to inhibit/enhance tumor cell growth in vitro. Melanoma Res. 7, S59-S65 (1997).
21. Hoon, D. S. B., Bowker, R. J. & Cochran, A. J. Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res. 47, 1529-1533 (1987).
22. Morton, D. L. & Cochran, A. J. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br. J. Dermatol. 151, 308-319 (2004). A critical analysis of the status of the SLN-removal technique (sentinel lymphadenectomy) in the management of patients with melanoma.
23. Cochran, A. J., Wen, D.-R. & Morton, D. L. Occult melanoma cells in the lymph nodes of patients with pathological Stage I malignant melanoma: an immunohistological study. Am. J. Surg. Pathol. 12, 612-618 (1988).
24. Wong, J. H., Cagle, L. A. & Morton, D. L. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann. Surg. 214, 637-641 (1991).
25. Morton, D. L. et al. Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann. Surg. 242, 302-311 (2005). Report of the first Multicenter Selective Lymphadenectomy Trial.
26. Cochran, A. J. et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumors. Pathology 36, 1-7 (2004).
27. Gershenwald, J. E. et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J. Clin. Oncol. 16, 2253-2260 (1998).
28. Gadd, M. A. et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch. Surg. 134, 381-387 (1999).
29. Jansen, L. et al. Reliability of sentinel lymph node biopsy for staging melanoma. Br. J. Surg. 87, 484-489 (2000).
30. Clary, B. M., Brady, M. S., Lewis, J. J. & Coit, D. G. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann. Surg. 233, 250-258 (2001).
31. Zogakis, T. G. et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch. Surg. 140, 865-871 (2005).
32. Morton, D. L. et al. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in clinical Stage I melanoma. J. Clin. Oncol. 23, 16s (2005).
33. Cochran, A. J., Roberts, A. A. & Saida, T. The place of lymphatic mapping and sentinel node biopsy in oncology. Int. J. Clin. Oncol. 8, 139-150 (2003).
34. Lee, J. H. et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J. Clin. Oncol. 22, 3677-3684 (2004).
35. Miyasaka, M. & Tanaka, T. Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nature Rev. Immunol. 4, 360-370 (2004).
36. Gimeno, M. J. et al. Modulatory role of IL-10 in endothelial cell damage and platelet adhesion. Histol. Histopathol. 18, 695-702 (2003).
37. Botella-Estrada, R. et al. Cytokine expression and dendritic cell density in melanoma sentinel nodes. Melanoma Res. 15, 99-106 (2005).
38. Hoon, D. S., Korn, E. L. & Cochran, A. J. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res. 47, 1740-1744 (1987).
39. Wang, S., Fan, P. & Wu, Z. Y. Preliminary study on lymphocyte subsets of sentinel lymph nodes in breast cancer patients. Zhonghua Zhong Liu Za Zhi 26, 220-222 (2004) (in Chinese).
40. Hirakawa, S. et al. VEGF-A induces tumour and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201, 1089-1099 (2005).
41. Haigh, P. I. et al. Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma. Cancer 92, 535-541 (2001). The first report of the use of particulate carbon to confirm that a lymph node is truly sentinel.
42. Morton, D. L. et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann. Surg. 238, 538-549 (2003).
43. Banchereau, J. et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767-811 (2000). A comprehensive review of the biology of DCs.
44. Huang, R.-R. et al. Modulation of paracortical dendritic cells and T lymphocytes in breast cancer sentinel nodes. Breast J. 6, 225-232 (2000). The first report of the immunology of cells of tumour-draining SLNs in patients with breast cancer.
45. Vermi, W. et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol. 200, 255-268 (2003).
46. Sakakura, K. et al. Infiltration of dendritic cells and NK cells into the sentinel lymph node in oral cavity cancer. Oral Oncol. 41, 89-96 (2005).
47. Ishigami, S. et al. Infiltration of antitumor immunocytes into the sentinel node in gastric cancer. J. Gastrointest. Surg. 7, 735-739 (2003).
48. Straten, P. T. et al. Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes. Cancer Immunol. Immunother. 55, 495-502 (2006).
49. Ross, R., Ross, X. L., Schwing, J., Langin, T. & Reske-Kunz, A. B. The actin-bundling protein fascin is involved in the formation of dendritic processes in maturing epidermal Langerhans cells. J. Immunol. 160, 3776-3782 (1998).
50. + dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res. 64, 2192-2198 (2004).
51. Inaba, K. et al. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T-cell areas of lymph nodes. J. Exp. Med. 186, 665-672 (1997).
52. Poindexter, N. J., Sahin, A., Hunt, K. K. & Grimm, E. A. Analysis of dendritic cells in tumour-free and tumour-containing sentinel nodes from patients with breast cancer. Breast Cancer Res. 6, R408-R415 (2004).
53. Schüle, J. M., Bergkvist, L., Håkansson, L., Gustafsson, B. & Håkansson, A. CD28 expression in sentinel node biopsies from breast cancer patients in comparison with CD3-ζ chain expression. J. Transl. Med. 2, 45 (2004).
54. Peguet-Navarro, J. et al. Gangliosides from human melanoma tumours impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170, 3488-3494 (2003).
55. Essner, R. & Kojima, M. Surgical and molecular approaches to the sentinel lymph nodes. Ann. Surg. Oncol 8 (Suppl. 9), 31-34 (2001).
56. Palucka, K. A., Taquet, N., Sanchez-Chapuis, F. & Gluckman, J. C. Dendritic cells as the terminal stage of monocyte differentiation. J. Immunol. 160, 4587-4595 (1998).
57. Geissmann, F. et al. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J. Exp. Med. 196, 417-430 (2002).
58. Leong, S. P., Peng, M., Zhou, Y. M., Vaquerano, J. E. & Chang, J. W. Cytokine profiles of sentinel lymph nodes draining the primary melanoma. Ann. Surg. Oncol. 9, 82-87 (2002). An innovative study of the cytokines present in melanoma-draining SLNs.
59. Essner, R. & Kojima, M. Dendritic cell function in sentinel nodes. Oncology (Williston Park) 16 (Suppl. 1), 27-31 (2002).
60. Yue, F. Y. et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int. J. Cancer 71, 630-637 (1997).
61. + T cells resulting in a failure to lyse tumour cells. Blood 93, 1634-1642 (1999).
62. + anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99, 2468-2476 (2002).
63. Takayama, T., Tahara, H. & Thomson, A. W. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumour growth. Transplantation 71, 1334-1340 (2001).
64. + T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103, 449-457 (2001).
65. Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol. 4, 762-774 (2004).
66. Munn, D. H. et al. Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase. Science 297, 1867-1870 (2002).
67. Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J. Exp. Med. 196, 459-468 (2002).
68. Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998).
69. Widner, B., Weiss, G. & Fuchs, D. Tryptophan degradation to control T-cell responsiveness. Immunol. Today 21, 250 (2000).
70. Murphy, P. M. et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176 (2000).
71. Dieu, M. C. et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188, 373-386 (1998).
72. Forster, R. et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99, 23-33 (1999).
73. Nakano, H. et al. Genetic defect in T lymphocyte-specific homing into peripheral lymph nodes. Eur. J. Immunol. 27, 215-221 (1997).
74. Willimann, K. et al. The chemokine SLC is expressed in T-cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur. J. Immunol. 28, 2025-2034 (1998).
75. Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 12, 121-127 (2000).
76. Moretta, A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nature Rev. Immunol. 2, 957-964 (2002).
77. Yoshida, R. et al. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J. Biol. Chem. 273, 7118-7122 (1998).
78. Geissmann, F. et al. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J. Exp. Med. 196, 417-430 (2002).
79. Yanagihara, S., Komura, E., Nagafune, J., Watarai, H. & Yamaguchi, Y. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J. Immunol. 161, 3096-3102 (1998).
80. Gunn, M. D. et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189, 451-460 (1999).
81. Gunn, M. D. et al. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc. Natl Acad. Sci. USA 95, 258-263 (1998).
82. Takeuchi, H. et al. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin. Cancer Res. 10, 2351-2358 (2004).
83. Hoon, D. S. B., Irie, R. F. & Cochran, A. J. Gangliosides from human melanoma immunomodulate the response of T cells to interleukin-2. Cell. Immunol. 111, 410-419 (1988).
84. Hoon, D. S. B. et al. Modulation of human macrophage functions by gangliosides. Immunol. Lett. 20, 269-276 (1989).
85. Cochran, A. J., Hoon, D. S. B., Korn, E. L., Ferraro, A. & Stene, M. Effect of indomethacin on the immunocompetence of human tumour-draining lymph nodes. Fed. Proc. 44, 965A (1985).
86. Gupta, R. K. & Morton, D. L. Studies of a melanoma tumour-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. J. Natl Cancer Inst. 72, 75-82 (1984).
87. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24, 1169-1177 (2006).
88. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173, 1444-1453 (2004).
89. + T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. 28,120-128 (2005).
90. + regulatory T cells in cancer patients. Blood 107, 2409-2414 (2006).
91. Hendrix, M., Seftor, E., Kirschmann, D., Quaranta, V. & Seftor, R. Remodeling of the microenvironment by aggressive melanoma tumour cells. Ann. NY Acad. Sci. 995, 151-161 (2003).
92. Littlepage, L. E., Egeblad, M. & Werb, Z. Coevolution of cancer and stromal cellular responses. Cancer Cell 7, 499-500 (2005).
93. Vaquero, J. & Martinez, R. Intratumoural immunotherapy with interferon-α and interleukin-2 in glioblastoma. Neuroreport 3, 981-983 (1992).
94. Ridoli, L. & Ridoli, R. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology 49, 335-339 (2002).
95. Vogelzang, N. J., Lestingi, T. M., Sudakoff, G. & Kradjian, S. A. Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions. Hum. Gene Ther. 5, 1357-1370 (1994).
96. Gupta, R., McElrath-Garza, A. & Morton, D. in From Melanocytes to Malignant Melanoma: The Progression to Malignancy (eds Hearing, V. J. & Leong, S. P. L.) 619-663 (Humana, Totowa, New Jersey, 2005).
97. Morton, D. et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann. Surg. 180, 635-643 (1974).
98. Rosenberg, S. A. & Rapp, H. J. Intralesional immunotherapy of melanoma with BCG. Med. Clin. North Am. 60, 419-430 (1976).
99. Radny, P. et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br. J. Cancer 89, 1620-1626 (2003).
100. Horton, H. M., Hernandez, P., Parker, S. E. & Barnhart, K. M. Antitumor effects of interferon-ω: in vivo therapy of human tumor xenografts in nude mice. Cancer Res. 59, 4064-4068 (1999).
101. Pan, P. Y. et al. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol. Immunother. 53, 17-25 (2004).
102. Dranoff, G. et al. Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumour immunity. Proc. Natl Acad. Sci. USA 90, 3539-3543 (1993).
103. Leong, S. P. et al. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumour regression in patients with metastatic melanoma. J. Immunother. 22, 166-174 (1999).
104. Dranoff, G. GM-CSF-based cancer vaccines. Immunol. Rev. 188, 147-154 (2002).
105. Sun, X., Hodge, L., Jones, H., Tabor, L. & Simecka, J. Co-expression of granulocyte-macrophage colonystimulating factor with antigen enhances humoral and tumour immunity after DNA vaccination. Vaccine 20, 1466-1474 (2002).
106. Kass, E., Panicali, D. L., Mazzara, G., Schlom, J. & Greiner, J. W. Granulocyte-macrophage colonystimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res. 61, 206-214 (2001).
107. Nakamura, M. et al. Dendritic cells genetically engineered to simultaneously express endogenous tumour antigen and granulocyte-macrophage colony-stimulating factor elicit potent therapeutic antitumour immunity. Clin. Cancer Res. 8, 2742-2749 (2002).
108. Pinedo, H. M. et al. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells. Eur. J. Cancer 39, 1061-1067 (2003).
109. Molenkamp, B. G. et al. Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am. J. Pathol. 167, 1301-1307 (2005). An innovative study of autologous skin and SLNs in patients with melanoma.
110. Vaquerano, J. E., Cadbury, P., Treseler, P. A., Sagebiel, R. W. & Leong, S. P. L. Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Arch. Dermatol. 135, 1276-1277 (1999).
111. Si, Z., Hersey, P. & Coates, A. S. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res. 6, 247-255 (1996).
112. Kawashima, N. et al. Delivery of dendritic cells engineered to secrete IFN-α into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J. Immunol. 175, 2730-2740 (2005).
113. Salcedo M. et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol. Immunother. 55, 819-829 (2006).
114. + T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22, 175-184 (2005).
115. Cyster, J. G. et al. Chemokines and B-cell homing to follicles. Curr. Top. Microbiol. Immunol. 246, 87-92 (1999).
116. Shackleton, M. et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4, 9 (2004).
117. Craft, N. et al. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J. Immunol. 175, 1983-1990 (2005).
118. Snow, H. Melanotic cancerous disease. Lancet 2, 872-874 (1892).